Calamos Advisors
PCRX icon

Calamos Advisors’s Pacira BioSciences PCRX Stock Holding History

Calamos Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,228
Closed -$2.84M – 1197
2022
Q1 		$2.84M Buy
+37,228
New +$2.48M 0.01% 851
2013
Q4 		– Sell
-475,195
Closed -$22.9M – 645
2013
Q3 		$22.9M Sell
475,195
-11,475
-2% -$418K 0.14% 161
2013
Q2 		$14.1M Buy
+486,670
New +$14.1M 0.09% 203

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Calamos Advisors's PCRX Position: Q2 2022 in Review

Calamos Advisors sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 37,228 shares — an estimated $2.84M sold.

Calamos Advisors first reported a position in PCRX in Q2 2013 and held it in 3 quarters. The position peaked at $22.9M in Q3 2013. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • Calamos Advisors reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • Calamos Advisors sold 37,228 Pacira BioSciences shares in Q2 2022, an estimated $2.84M.
  • Calamos Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 3 quarters.
  • Calamos Advisors's Pacira BioSciences position peaked at $22.9M in Q3 2013.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.